Cancer-Associated Thrombosis in Cirrhotic Patients with Hepatocellular Carcinoma. [PDF]
, 2018 It is common knowledge that cancer patients are more prone to develop venous thromboembolic complications (VTE). It is therefore not surprising that patients with hepatocellular carcinoma (HCC) present with a significant risk of VTE, with the portal vein
Burra, P +5 more
core +1 more source
Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations [PDF]
Journal of Stroke, 2018 Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis.
Kazunori Toyoda +2 more
doaj +1 more source
Allosteric Inhibition of Factor XIIIa. Non-Saccharide Glycosaminoglycan Mimetics, but Not Glycosaminoglycans, Exhibit Promising Inhibition Profile [PDF]
, 2016 Factor XIIIa (FXIIIa) is a transglutaminase that catalyzes the last step in the coagulation process. Orthostery is the only approach that has been exploited to design FXIIIa inhibitors.
Afosa, Daniel K. +4 more
core +4 more sources
New horizons in anticoagulation: Direct oral anticoagulants and their implications in oral surgery.
Medicina oral, patologia oral y cirugia bucal, 2017 Thrombotic disorders remain a leading cause of death in the Western World. For decades, vitamin K antagonists used in the prevention of this pathology, such as warfarin or sintrom, were the only oral agents available for long-term anticoagulation, in spite of their disadvantages.An electronic database search was carried out on MedLine and The Cochrane ...
V Serrano-Sánchez +7 more
openaire +4 more sources
Role of rivaroxaban in the management of atrial fibrillation: insights from clinical practice. [PDF]
, 2018 © 2018 Vimalesvaran et al. This work is published and licensed by Dove Medical Press Limited.Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and it leads to significant morbidity and mortality, predominantly from ischemic stroke.
Dockrill, Seth J +2 more
core +3 more sources
Guidance for Endoscopic Procedures in Patients Taking Novel Oral Anticoagulants
The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2016 Anticoagulant agents are used to reduce the risk of thromboembolic complications in patients with atrial fibrillation or deep vein thrombosis. Several new generation of oral anticoagulants have been approved.
Kyoung Oh Kim
doaj +1 more source
Type of atrial fibrillation and clinical outcomes in patients with heart failure and reduced ejection fraction [PDF]
, 2017 Background: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. Objectives: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 ...
Abraham, William T. +11 more
core +3 more sources
Assessment and predictors of inappropriate dose of direct oral anticoagulants
Italian Journal of MedicineDirect-Acting Oral Anticoagulants (DOACs) have revolutionized the management of Atrial Fibrillation (AF) and Venous Thromboembolism (VTE). However, recent audits reveal a significant burden of inappropriate dosages in the prescribing of direct-acting ...
Mosaad O. Almegren
doaj +1 more source
A Review of the Incidence Diagnosis and Treatment of Spontaneous Hemorrhage in Patients Treated with Direct Oral Anticoagulants [PDF]
, 2020 Anticoagulation carries a tremendous therapeutic advantage in reducing morbidity and mortality with venous thromboembolism and atrial fibrillation.
Chandran, Arul +6 more
core +1 more source
Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation [PDF]
, 2016 This is an Accepted Manuscript of an article published by Taylor & Francis GroupNon-vitamin K antagonist oral anticoagulants (NOACs) reduce the risk of thromboembolism in patients with atrial fibrillation (AF).
Artman, Benjamin +8 more
core +2 more sources